Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls
Primary result · CTXResult — go to the resultAdjusted difference −0.183 95% CI −0.352 to −0.013Authors' conclusion
Patients with AVP-D showed reduced CTX levels and consequently an increased P1NP/CTX ratio compared to HC, whereas no difference was observed between patients with PP and both groups. Overall, these findings do not support major bone metabolic alterations with detrimental effects in AVP-D.
Study context
- Population
- Patients with AVP deficiency (AVP-D), primary polydipsia (PP) and healthy controls (HC), excluding chronic steroid therapy, prior osteoporotic fractures, long-term antiresorptive treatment or bone-affecting medications; June 2023 to June 2024
- Participants
- 46 patients
- Comparison
- AVP-D vs PP vs HC
- AVP-Dn = 11
- PPn = 13
- HCn = 22reference
- Primary endpoint
- Bone turnover markers (CTX, P1NP)
Methodological detailscomparative, Conducted June 2023 to June 2024
- Comparative
- Conducted June 2023 to June 2024
Primary result
CTX
Adjusted difference
−0.183
95% CI −0.352 to −0.013
P = 0.036
By group
AVP-Dvs HC
adjusted difference −0.183 (95% CI −0.352 to −0.013); P = 0.036
As reported in the abstract
Further findings
| Outcome | P value |
|---|---|
| P1NP/CTX ratio (bone formation index)AVP-D vs HC · higher with AVP-D | P = 0.036 |
| 25OH-vitamin DAVP-D vs HC · lower with AVP-D | P = 0.031 |
P1NP/CTX ratio (bone formation index)
- No difference between PP and either group
Serum calcium, phosphate and P1NP
- Comparable across groups
Original publication
Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls. J Clin Endocrinol Metab. Published 7 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →